The inflamed tissue landscape is constantly changing: vasculature is leaky, proteases are over-expressed, and surface epitopes are up- and down-regulated within hours. In order to be successful, peptides must act as vascular keys and metabolic chameleons, locking onto transiently exposed receptors, surviving oxidative bursts, and releasing payloads before the microenvironment returns to a resting state. It requires that one short sequence encode pH-sensitive switches, protease-cleavable linkers, and shear-activated anchors that can sense, adapt and self-neutralize when the inflammatory response subsides.
The beauty of inflammatory settings is that the target is not a homogenous line of cells but a dynamic patchwork: endothelial adhesion molecules turn on within minutes, cytokine receptors up-regulate within hours, and protease activity spikes within days. In consequence, conventional "healthy-tissue" peptides don't work because they are optimized for homeostatic biology—they are blind to the transient epitopes that characterize the lesion. Peptides that do work are conditional, not constitutive: they bind only where MMP-9 is active, cleave only where pH is low, and release payload only inside the inflamed lysosome.
External and intrinsic factors fueling an inflammatory microenvironment.1,5
Histamine, bradykinin and complement fragments (C3a, C5a) also induce transient phosphorylation of VE-cadherin, opening inter-endothelial gaps for extravasation of plasma proteins and nanoparticles. Peptides may take advantage of these transitory gaps by incorporating short mildly hydrophobic segments, which inserts into leaky glycocalyx and thus allows them to "surf" the permeability wave before junctions are resealed. Chemokine fields in inflamed tissues create concentric rings around sites of inflammation that are used by neutrophils and monocytes for navigation along CXCL8 or CCL2 gradients. Peptides that present chemokine-mimetic loops can therefore "hitchhike" on migrating leukocytes, using the leukocytes themselves as Trojan horses to reach deeper tissue layers that are inaccessible to passive diffusion.
Expression of ICAM-1 or VCAM-1 is at a maximum within hours and reduces as levels of IL-6 fall. So ligands optimized for maximal expression will often bind weakly at resolution. Peptides containing pH dependent histidines, however, have an affinity that is restored at the acidic pH seen at sites of active inflammation before being released as the pH normalizes. This can be used to more closely match the kinetics of binding to that of the inflammatory process. Variable receptor density seen between septic, autoimmune and traumatic inflammation has led to failure from batch to batch of non-dynamic ligands. The addition of shear-activated lipophilic anchors which only insert into the cell membrane under conditions of high flow provides a mechanical rather than molecular on-off switch, that allows selective uptake only in hyperaemic tissue regardless of cytokine environment.
Table 1 Inflammatory vs healthy tissue: targeting parameter shifts
| Parameter | Healthy tissue | Inflamed tissue | Peptide design response |
| Junction integrity | Tight | Loose | Hydrophobic insertion |
| Surface ICAM-1 | Low | High & transient | pH-sensitive loop |
| Interstitial pH | 7.4 | 6.5–6.8 | Histidine protonation |
| Flow shear | Low | High | Shear-activated anchor |
| Protease activity | Basal | Elevated | D-amino-acid shield |
Inflammatory lesions are biochemical storms: within hours, receptor density, protease activity and oxidative potential change dramatically, so that yesterday's high-affinity epitope becomes today's truncated remnant. Successful peptides therefore encode environmental sensors—pH-labile linkers, redox-cleavable disulfides, protease-resistant backbones—rather than chase static ultra-high affinity.
In the setting of a healthy endothelium the glycocalyx is in a quiescent state; following inflammation ICAM-1, VCAM-1 and E-selectin are up-regulated within minutes, however maximum expression is reached as the levels of IL-6 subside. Peptides designed to sequester these inducible epitopes therefore need to include pH-sensitive histidines or reducible disulfides that increase off-rate when the environment is re-acidified, to prevent the ligand remaining bound to the now-reverting endothelium. On the other hand constitutive markers such as CD31 are present on all endothelium but have no disease specificity, forcing a designer to take a Boolean-logic approach in which two moderate-affinity ligands must be present simultaneously to reach pathologic selectivity. Receptor density may also increase and decrease within the space of a circadian cycle, causing batch-to-batch failure of static ligands. Installing a shear-activated lipophilic anchor that inserts only at high flow, provides a mechanical as opposed to molecular gate, that ensures uptake occurs only in the setting of active hyperaemia regardless of cytokine oscillations. Since the same peptide can be engineered to release at pH 6.0 but re-bind at pH 7.4, a single sequence can be turned on and off the receptor multiple times, maximizing payloads delivered per cell without saturating the pathway.
Inflammatory foci are rich in matrix metalloproteinases, cathepsins and neutrophil elastase that have a preference for cleaving after basic or hydrophobic residues. As such, linear peptides are rapidly truncated, whereas head-to-tail cyclisation or D-alanine incorporation at positions 2 and 13 prevent exopeptidase attack. In addition, because oxidative species can oxidize methionine and tryptophan side-chains, designers often substitute these residues with norleucine or oxanorbornyl analogues that are hydrophobic, but that are resistant to ROS, tuning protease stability to oxidative stability. Coupling of the peptide to a PEG or hydrogel network via covalent linkers protects the backbone from bulk protease diffusion, but still allows access of cell-surface proteases to a deliberately exposed loop for on-demand release. This "tethered but vulnerable" architecture allows the peptide to remain intact during transit in the vasculature, but is only trimmed after receptor engagement, affording temporal control of targeting as well as payload release.
Histamine and bradykinin open endothelial gaps through which nanoparticles up to 200 nm in diameter can extravasate. The same gaps also expose basement membrane heparan sulfate, which adsorbs cationic peptides. To avoid this "perivascular sink", designers have added short, mildly hydrophobic stretches which insert into the leaky glycocalyx, effectively "surfing" the permeability wave before junctions reseal. Because the peptide can be engineered to release at pH 6.0 yet re-bind at pH 7.4, one sequence can cycle on and off the receptor multiple times, maximizing brain exposure without accumulating in the vessel wall. Neutrophils and inflammatory monocytes scavenge foreign particles via complement and Fc receptors; even charge-neutral peptides can be opsonised if they expose hydrophobic patches after proteolytic nicking. Shielding the peptide with a short PEG tail or installing zwitterionic glutamate residues reduces opsonisation while preserving receptor-mediated uptake, ensuring that the payload reaches the intended parenchymal cell rather than being trapped in hepatic or splenic macrophages.
Table 2 Inflammation Feature vs Peptide Design Response
| Microenvironment Feature | Peptide-Level Countermeasure | Translational Risk |
| Transient epitope | pH-cleavable linker | Premature plasma cleavage |
| Protease surge | D-amino acid backbone | Immunogenicity |
| Leaky vasculature | Zwitterionic shield | Masked binding epitope |
| Oxidative burst | Oxidation-resistant analogs | Reduced cleavability |
Selecting a peptide target within an inflamed tissue is less about finding a "unique" feature and more about selecting a molecular or micro-environmental signature that can be present early in the disease process, remains for a sufficient period of time to allow for drug action, and then is no longer present during the resolution of inflammation. These designers must therefore balance micro-environment-specific cues (pH, enzymes, ECM neo-epitopes) with those of cell-restricted epitopes (activation markers), and then layer temporal logic (acute vs chronic) to avoid binding to a transient epitope that is no longer present once the cytosolic delivery portion of the process is complete.
Regulation of inflammatory signaling pathways by plant-derived bioactive peptides.2,5
Inflammation leads to metalloproteinase cleavage of collagen, fibronectin and laminin, generating neo-epitopes (e.g., EDP of type IV collagen) not present in the native matrix. Target peptides recognise these cryptic sequences so bind to a "scar" rather than a cell, allowing expression to be independent of leukocyte infiltration and remain elevated for days. As ECM is immobile, the peptide can accumulate payload locally while using the fiber as a scaffold for sustained release, so depot formation is coupled to tissue repair rather than immune suppression. CD69, CD25 or PD-L1 are expressed on T-cells and macrophages within hours of activation, but decline as cytokine levels subside. Targeting these epitopes therefore requires on-rates fast enough to engage under shear flow and off-rates rapid enough to detach when the cell reverts to a resting state. Designers graft pH-sensitive histidines that protonate in acidified endosomes, which accelerates release before receptor down-regulation.
Acute settings (sepsis, trauma) have very rapid receptor up-regulation, but also very rapid resolution; these peptides need to deliver their payload in 6–12 h or be washed away by oedema fluid. In chronic diseases (rheumatoid arthritis, diabetic ulcers) the receptor remains expressed at low-grade for weeks, so moderate-affinity ligands can accumulate more slowly. Chronic sites also fibrose, so designers prefer ECM-targeting peptides that bind deposited collagen fragments. These provide a depot that outlasts cellular fluctuations, and so match residence time to disease timescale. When receptors like ICAM-1 can surge and decline under a course of corticosteroid therapy, batches of static ligands fail in a non-deterministic way. By incorporating a shear-activated lipophilic anchor that inserts only under high-flow conditions, the peptide has a mechanical (rather than molecular) gate and will only be taken up during active hyperaemia, regardless of cytokine oscillations. Because the same peptide can be engineered to release at pH 6.0 yet re-bind at pH 7.4, a single sequence can cycle on and off the receptor multiple times, maximising the number of payloads delivered per disease flare, without saturating the pathway.
Engineering peptides to traffic to inflamed tissue is an exercise in molecular determinism in the face of biological entropy. Inflammation changes vascular permeability, the levels of receptors and proteases expressed on cells, and can remodel extracellular matrix proteoglycans within hours. Therefore peptides need to have conditional release built into them as well as tempered binding affinity rather than static ultra-high affinity binding. In order for a peptide to be successful in targeting inflamed tissues it must be engineered with the understanding that it must "settle" for multiple compromises. Moderately strong affinity is compromised with more reversible binding. A cyclized peptide backbone is used to compromise the peptide with resistance to proteases, and the charge of peptides is often masked to prevent non-specific cellular uptake. The same drug needs to be able to function in both an acute cytokine storm and a chronic fibrotic scar without the peptide or carrier becoming the danger signal itself.
Ultra-high affinity (<1 nM) can sequester the peptide–drug conjugate in the first row of inflamed endothelium, which forms a "binding-site barrier" against further penetration into the lesion. Developers therefore calibrate dissociation constants to 10–100 nM and equip pH-labile linkers that attenuate receptor interaction once the vesicle acidifies, to promote abluminal release while the peptide itself recycles back to blood. Inflammatory receptors (VCAM-1, ICAM-1) are up-regulated within hours and can be shed or internalized within 12 h. Peptides must therefore achieve rapid on-rates (<1 min) to engage during the brief capillary transit yet moderate off-rates to allow multiple binding events per cell, amplifying cumulative gene silencing without receptor saturation.
MMP-2, MMP-9, and cathepsins are 5- to 50-fold overexpressed, and cleave linear peptides within minutes. Backbone N-methylation, D-amino acid substitution or the addition of thioether staples, build protease-resistant scaffolds which can resist the "soup" of proteases within the inflammatory milieu and remain cleavable once inside target cells via reducing conditions. These modifications also lower affinity for the target receptor, and so to improve stability without compromising binding potential, developers are forced to carefully balance these two factors using iterative phage selection. Oxidative burst by neutrophils results in the generation of H2O2 which oxidizes methionine and cysteine, causing conformational changes that result in aggregation. This can be circumvented by substituting oxidation resistant analogs (norleucine for Met, thioether for Cys), while maintaining redox-cleavable properties for payload release in the cytosol.
Leaky vasculature also allows serum albumin, a protein which will compete for peptide binding. For this reason, developers modify the peptide to include zwitterionic or sulfated residues that repel albumin without compromising receptor affinity. pH-titratable histidines can also be included, which remain neutral at blood pH but are protonated and membrane-active in acidic endosomes, thereby "turning on" membrane activity only after the peptide has bound its receptor. High-density (>50 peptides per liposome) results in 80–120 nm clusters that are rapidly cleared by Kupffer cells. Low-density (10–20 peptides) produces 30–50 nm particles that can avoid phagocytes while still binding to target receptors. Protease-cleavable PEG shields that shed after tissue entry can restore native surface charge and reduce off-target adhesion to healthy organs. Neutrophils and inflammatory monocytes are constantly scavenging foreign particles through complement and Fc receptors; even peptides with a net-neutral charge can be opsonized if they expose a hydrophobic patch when they are nicked proteolytically. Shielding the peptide with a short PEG tail or installing zwitterionic glutamate residues can reduce opsonization without compromising receptor-mediated uptake, and ensure that the payload gets to the intended parenchymal cell rather than getting stuck in hepatic or splenic macrophages. Because the same peptide can be engineered to release at pH 6.0 yet re-bind at pH 7.4, one sequence can cycle on and off the receptor many times, delivering the maximum number of payloads per cell without saturating the pathway.
Designing peptides for inflamed tissue is less about the identification of a "universal" marker and more about the engineering of a ligand that can sense, adapt and self-neutralize within a micro-environment that can change hour by hour. The same sequence must display nanomolar affinity under acidic, protease-rich conditions yet dissociate once pH normalizes; it must resist oxidative cleavage yet cleave itself once inside the target cell; and it must avoid the "perivascular sink" created by leaky vasculature while still exploiting that leakiness to enter the lesion. Because each optimisation axis influences the others (e.g. increasing affinity often increases retention), the final construct is always a compromise rather than a perfect ligand.
Rheumatoid synovium is characterized by hypoxic, CD206-high macrophages, whereas psoriatic plaques are hyperoxic and IL-23-dominated; the ICAM-1 peptide that binds well in RA would thus be outcompeted by soluble ICAM-1 in psoriasis, and exhibit batch-to-batch failure. Designers use Boolean-logic approaches (conjugating two moderate-affinity ligands with a protease-cleavable linker in between) so that only cells that express both epitopes internalize the full payload, improving the therapeutic index without increasing peptide size beyond renal filtration cut-off. A peptide that was optimized for acute myocarditis (high shear, transient expression of ICAM-1) would have suboptimal uptake in chronic diabetic ulcers, where receptors are constitutive but density is low. Embedding a shear-activated lipophilic anchor which inserts only under high-flow conditions provides a mechanical rather than molecular gate, ensuring uptake occurs only in active hyperaemia regardless of cytokine milieu, aligning the targeting with the disease tempo rather than the disease type.
As leaky vasculature permits extravasation of particles up to 200 nm in size, the simple charge-neutrality of these peptides can already direct their passive accumulation, leading to a "background signal" of non-specific, passive entrapment that masks the desired receptor-mediated uptake. The former issue is countered by installing pH-sensitive histidines that only protonate once inside acidified endosomes, thereby restricting the release to cells that have undergone active, receptor-mediated internalization (as opposed to passive entrapment), and thereby restoring signal-to-noise ratio without changing blood exposure levels. Expression levels of basal ICAM-1 on healthy endothelium can reach 60 % of maximal levels during inflammation, leading to essentially equal binding of high-avidity ligands. Lowering the ligand density to 20 % of maximum surface coverage (instead of 100 %) can restore selectivity according to expression level differences as shown by PET imaging in inflammation models of the lung. This so-called "avidity dial" approach ties the binding probability to the amount of receptors on the cell surface, transforming a continuous expression gradient into a threshold-like uptake switch.
Table 3 Cross-disease heterogeneity and peptide design trade-offs
| Parameter | Acute inflammation | Chronic inflammation | Design compromise |
| Receptor density | High & transient | Low & constitutive | Moderate affinity |
| Flow shear | High | Low | Shear-activated anchor |
| Protease activity | Surge | Mild | D-amino-acid shield |
| Background ICAM | 60 % of peak | 30 % of peak | 20 % ligand density |
| pH gradient | Strong | Weak | Histidine count tuning |
Peptide ligands are most effective where the inflammatory lesion presents a stable molecular gradient (persistent up-regated receptor, or ECM neo-epitope) that is accessible for >12 h. Peptides can be cyclized or D-amino-acid stabilized in days, so are suited to localized, compartmentalised inflammation (joint, gut mucosa, tumor bed) where vascular leak is moderate but not chaotic, where receptor expression is disease-associated and not acute-phase. Strategy fails where the flare is systemic or self-limits within hours because renal clearance outruns receptor accumulation.
Fibronectin-EDA, tenascin-C, and MMP-cleaved collagen are essentially undetectable in healthy tissue, but become deposited within hours of cytokine exposure. Peptides discovered against these neo-epitopes therefore have broad applicability across rheumatoid arthritis, psoriasis, and cancer because the target is the lesion itself rather than a single cell lineage. Furthermore, ECM components are immobile, so moderate affinity (100 nM) is sufficient because the peptide has minutes rather than seconds to engage. Developers therefore perform phage display against protease-digested ECM fragments to discover sequences that bind the cleaved neo-epitope but not the intact parent protein. This feature ensures that uptake occurs only where protease activity is high. Inflamed tissues have steep pH gradients (6.2–6.8 in alveolar fluid vs 7.4 in blood) and redox bursts (H2O2 10–100 µM). pH-titratable histidine residues or redox-cleavable disulfide linkers can be engineered to activate only within this pathological window, ensuring that payload release is tied to peak inflammation rather than a convenient sampling time. Moreover, the gradient is stable for days in chronic lesions, providing a temporal window for repeat dosing without receptor saturation.
Acute lung injury has peak severity at 6–12 h and complete resolution within 24 h; a peptide optimized at 24 h will miss the therapeutic window. Under these conditions, cell-hitchhiking strategies (e.g. neutrophil-templated albumin nanoparticles that simply ride the cellular wave to the lesion) achieve faster accumulation than receptor-mediated transcytosis, accepting transient barrier disruption as an acceptable trade-off for speed. Cytokine storm during sepsis involves multiple organs with overlapping receptor expression; a peptide that binds ICAM-1 will also accumulate in liver, lung and kidney, risking multi-organ toxicity. Systemic JAK inhibitors or anti-TNF antibodies achieve faster pharmacokinetics and broader coverage, accepting off-target toxicity as an acceptable trade-off for speed and whole-body suppression.
Inflammatory microenvironments differ fundamentally from healthy tissues and tumors. Dynamic target expression, elevated protease activity, oxidative stress, and increased vascular permeability create conditions where many targeting peptides lose stability or specificity. Programs often fail not because peptides cannot bind inflammatory targets, but because designs do not account for the transient and heterogeneous nature of inflammation. Our targeting peptide services support inflammation-targeted drug delivery by integrating microenvironment biology, stability-aware design, and feasibility assessment into a unified development strategy.
Inflammation-Specific Target Evaluation: Effective targeting in inflammatory settings begins with selecting targets that are not only disease-relevant, but also sufficiently persistent and accessible within inflamed tissues. Our inflammation-specific target evaluation focuses on markers that are upregulated or uniquely exposed in inflammatory microenvironments, such as activated immune cell receptors, extracellular matrix components, or inflammation-induced surface proteins. We assess how target expression varies across disease stages, tissue compartments, and inflammatory intensity. This helps ensure that peptide targeting is driven by microenvironment-specific biology rather than nonspecific accumulation caused by increased permeability.
Stability-Driven Sequence Optimization: Inflamed tissues often present harsh biochemical conditions, including high protease activity and oxidative stress, which can rapidly degrade conventional peptide sequences. Our stability-driven sequence optimization approach designs peptides to maintain structural and functional integrity under these conditions. Sequence modifications are guided by known degradation pathways in inflammatory environments, with careful balancing to preserve targeting affinity and reversibility. By prioritizing stability alongside selectivity, we reduce the risk of peptides losing function before reaching or engaging their intended targets.
Target Persistence Analysis: A key challenge in inflammation-targeted delivery is the transient nature of many inflammatory markers. Our feasibility assessment includes a target persistence analysis that evaluates how long a target remains accessible and relevant during disease progression. Targets that fluctuate rapidly or disappear as inflammation resolves are identified early, helping teams avoid designs that may perform inconsistently or fail to translate across disease models.
Early Off-Target Risk Identification: Inflammatory microenvironments increase the risk of non-specific uptake due to leaky vasculature and immune cell infiltration. We focus on early off-target risk identification to assess whether observed accumulation is likely driven by true targeting or by inflammation-induced nonspecific effects. This early distinction helps refine peptide design or redirect targeting strategies before extensive optimization efforts are undertaken.
If your inflammation-targeted program shows high background uptake, inconsistent tissue localization, or loss of targeting specificity under inflammatory conditions, an early technical discussion can help identify whether microenvironment biology or peptide design is the limiting factor. Discuss your inflammation targeting strategy with our scientists to evaluate target suitability, identify stability and specificity risks, and define a peptide design approach aligned with the realities of inflammatory microenvironments.
References
